Header Logo

Connection

HOWARD WEINER to Adult

Back to Details
This is a "connection" page, showing publications HOWARD WEINER has written about Adult.
HOWARD WEINER
Connection Strength
1.072
Adult
  1. Stool Glial Fibrillary Acidic Protein Is Elevated in Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Nov; 12(6):e200466.
    View in: PubMed
    Score: 0.053
  2. Glial Activity Load on PET Reveals Persistent "Smoldering" Inflammation in MS Despite Disease-Modifying Treatment: 18 F-PBR06 Study. Clin Nucl Med. 2024 Jun 01; 49(6):491-499.
    View in: PubMed
    Score: 0.048
  3. Pediatric Vagus Nerve Stimulation: Case Series Outcomes and Future Directions. Neurosurgery. 2023 05 01; 92(5):1043-1051.
    View in: PubMed
    Score: 0.044
  4. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. Front Immunol. 2021; 12:709861.
    View in: PubMed
    Score: 0.040
  5. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
    View in: PubMed
    Score: 0.037
  6. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. J Neuroimaging. 2018 01; 28(1):36-47.
    View in: PubMed
    Score: 0.031
  7. Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017 11 17; 8(1):1600.
    View in: PubMed
    Score: 0.031
  8. Identification and characterization of latency-associated peptide-expressing ?d T cells. Nat Commun. 2015 Dec 08; 6:8726.
    View in: PubMed
    Score: 0.027
  9. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics. 2013 Jan; 10(1):77-88.
    View in: PubMed
    Score: 0.022
  10. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.020
  11. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):75-9.
    View in: PubMed
    Score: 0.018
  12. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.017
  13. Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis. Mult Scler. 2026 Aug; 32(9):972-984.
    View in: PubMed
    Score: 0.014
  14. Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis. Cell Rep. 2026 Jun 23; 45(6):117417.
    View in: PubMed
    Score: 0.014
  15. Brain-age defines a structural signature of outcomes after vagus nerve stimulation in children. Brain Stimul. 2026 Jul-Aug; 19(4):103117.
    View in: PubMed
    Score: 0.014
  16. Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. J Neurol Neurosurg Psychiatry. 2025 Oct 15; 96(11):1046-1052.
    View in: PubMed
    Score: 0.013
  17. Research experience, goals, and priorities of pediatric neurosurgeons: a survey of the American Society of Pediatric Neurosurgeons. J Neurosurg Pediatr. 2025 Oct 10; 36(6):779-788.
    View in: PubMed
    Score: 0.013
  18. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler. 2005 Oct; 11(5):573-82.
    View in: PubMed
    Score: 0.013
  19. Spatiotemporal Mapping of Auditory Onsets during Speech Production. J Neurosci. 2024 11 20; 44(47).
    View in: PubMed
    Score: 0.013
  20. A survey of the members of the American Society of Pediatric Neurosurgeons and factors associated with well-being. J Neurosurg Pediatr. 2024 11 01; 34(5):537-545.
    View in: PubMed
    Score: 0.012
  21. Meta-analysis identifies common gut microbiota associated with multiple sclerosis. Genome Med. 2024 07 31; 16(1):94.
    View in: PubMed
    Score: 0.012
  22. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nat Commun. 2024 May 20; 15(1):4297.
    View in: PubMed
    Score: 0.012
  23. Responsive Neurostimulation for the Treatment of Children With Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. Pediatr Neurol. 2023 08; 145:97-101.
    View in: PubMed
    Score: 0.011
  24. Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Mult Scler Relat Disord. 2022 Jun; 62:103793.
    View in: PubMed
    Score: 0.010
  25. Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery. 2002 Apr; 50(4):727-33; discussion 733-4.
    View in: PubMed
    Score: 0.010
  26. Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022 03; 9(2).
    View in: PubMed
    Score: 0.010
  27. Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome. Nat Commun. 2021 12 06; 12(1):7078.
    View in: PubMed
    Score: 0.010
  28. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.010
  29. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.010
  30. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery. 2000 Dec; 47(6):1400-9.
    View in: PubMed
    Score: 0.010
  31. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020 09 01; 143(9):2733-2741.
    View in: PubMed
    Score: 0.009
  32. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. Neurol Neuroimmunol Neuroinflamm. 2020 11; 7(6).
    View in: PubMed
    Score: 0.009
  33. Serum antibodies to phosphatidylcholine in MS. Neurol Neuroimmunol Neuroinflamm. 2020 07; 7(4).
    View in: PubMed
    Score: 0.009
  34. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Oct; 267(10):2790-2796.
    View in: PubMed
    Score: 0.009
  35. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.009
  36. Pediatric intramedullary spinal cord tumors: special considerations. J Neurooncol. 2000 May; 47(3):225-30.
    View in: PubMed
    Score: 0.009
  37. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. J Neuroimaging. 2020 03; 30(2):212-218.
    View in: PubMed
    Score: 0.009
  38. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.009
  39. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.009
  40. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e587.
    View in: PubMed
    Score: 0.009
  41. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.008
  42. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019 10; 25(12):1605-1617.
    View in: PubMed
    Score: 0.008
  43. 18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis. Clin Nucl Med. 2018 Sep; 43(9):e289-e295.
    View in: PubMed
    Score: 0.008
  44. Pro-inflammatory activation of microglia in the brain of patients with sepsis. Neuropathol Appl Neurobiol. 2019 04; 45(3):278-290.
    View in: PubMed
    Score: 0.008
  45. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.008
  46. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
    View in: PubMed
    Score: 0.008
  47. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.008
  48. Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome. Pediatr Neurosurg. 1997 Jul; 27(1):12-8.
    View in: PubMed
    Score: 0.008
  49. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.007
  50. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.007
  51. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon ?-1a in MS. Neurology. 2016 Oct 04; 87(14):1464-1472.
    View in: PubMed
    Score: 0.007
  52. A novel computer-assisted volumetric stereotactic approach for resecting tumors of the posterior parahippocampal gyrus. J Neurosurg. 1996 Aug; 85(2):272-7.
    View in: PubMed
    Score: 0.007
  53. Pediatric brain tumors express multiple receptor tyrosine kinases including novel cell adhesion kinases. Pediatr Neurosurg. 1996 Aug; 25(2):64-71; discussion 71-2.
    View in: PubMed
    Score: 0.007
  54. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2017 May; 127(5):396-403.
    View in: PubMed
    Score: 0.007
  55. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. J Autoimmun. 2016 08; 72:8-18.
    View in: PubMed
    Score: 0.007
  56. Tuberous Sclerosis Health Care Utilization Based on the National Inpatient Sample Database: A Review of 5655 Hospitalizations. World Neurosurg. 2016 Jul; 91:97-105.
    View in: PubMed
    Score: 0.007
  57. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12; 387(10023):1075-1084.
    View in: PubMed
    Score: 0.007
  58. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Ann Neurol. 2016 Feb; 79(2):178-89.
    View in: PubMed
    Score: 0.007
  59. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.007
  60. Current treatment of normal-pressure hydrocephalus: comparison of flow-regulated and differential-pressure shunt valves. Neurosurgery. 1995 Nov; 37(5):877-84.
    View in: PubMed
    Score: 0.007
  61. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.007
  62. [Assessment of grief exemplified pregnancy loss: development and initial results on the validity of the Munich Grief Scale]. Psychother Psychosom Med Psychol. 1995 Sep-Oct; 45(9-10):295-302.
    View in: PubMed
    Score: 0.007
  63. Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. Circ Res. 2015 Oct 09; 117(9):779-92.
    View in: PubMed
    Score: 0.007
  64. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol. 2015 Jul; 78(1):115-27.
    View in: PubMed
    Score: 0.006
  65. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery. 1994 Dec; 35(6):1001-10; discussion 1010-1.
    View in: PubMed
    Score: 0.006
  66. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.006
  67. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia. 2014 Jul; 55(7):1025-9.
    View in: PubMed
    Score: 0.006
  68. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90.
    View in: PubMed
    Score: 0.006
  69. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology. 2014 Jun 17; 82(24):2173-9.
    View in: PubMed
    Score: 0.006
  70. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.006
  71. Surgery for angiographically occult cerebral aneurysms. J Neurosurg. 1993 Nov; 79(5):674-9.
    View in: PubMed
    Score: 0.006
  72. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013 Dec; 49(6):439-44.
    View in: PubMed
    Score: 0.006
  73. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. J Oncol Pharm Pract. 2014 Jun; 20(3):229-32.
    View in: PubMed
    Score: 0.006
  74. Cervical laminectomy and foraminotomy as surgical treatment of cervical spondylosis: a follow-up study with analysis of failures. J Spinal Disord. 1993 Jun; 6(3):245-50; discussion 250-1.
    View in: PubMed
    Score: 0.006
  75. Longitudinal quantitative analysis of the tuber-to-brain proportion in patients with tuberous sclerosis. J Neurosurg Pediatr. 2013 Jul; 12(1):71-6.
    View in: PubMed
    Score: 0.006
  76. Brain MR spectroscopic abnormalities in "MRI-negative" tuberous sclerosis complex patients. Epilepsy Behav. 2013 May; 27(2):319-25.
    View in: PubMed
    Score: 0.006
  77. The ability of high field strength 7-T magnetic resonance imaging to reveal previously uncharacterized brain lesions in patients with tuberous sclerosis complex. J Neurosurg Pediatr. 2013 Mar; 11(3):268-73.
    View in: PubMed
    Score: 0.006
  78. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1829-39.
    View in: PubMed
    Score: 0.005
  79. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24; 380(9856):1819-28.
    View in: PubMed
    Score: 0.005
  80. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.005
  81. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
    View in: PubMed
    Score: 0.005
  82. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.005
  83. Medically refractory epilepsy in autism. Epilepsia. 2011 Jun; 52(6):1071-5.
    View in: PubMed
    Score: 0.005
  84. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.005
  85. The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging. 2012 Apr; 22(2):129-36.
    View in: PubMed
    Score: 0.005
  86. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.005
  87. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.005
  88. Intrathecal baclofen therapy: complication avoidance and management. Childs Nerv Syst. 2011 Mar; 27(3):421-7.
    View in: PubMed
    Score: 0.005
  89. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009 Nov; 16(3):454-60.
    View in: PubMed
    Score: 0.004
  90. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.004
  91. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 02; 72(22):1922-30.
    View in: PubMed
    Score: 0.004
  92. Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb; 66(2):234-7.
    View in: PubMed
    Score: 0.004
  93. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.004
  94. Intracranial microvascular free flaps. J Reconstr Microsurg. 2009 Feb; 25(2):89-95.
    View in: PubMed
    Score: 0.004
  95. Epilepsy surgery in tuberous sclerosis complex: early predictive elements and outcome. Childs Nerv Syst. 2008 Dec; 24(12):1437-45.
    View in: PubMed
    Score: 0.004
  96. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.004
  97. Cortical abnormalities in epilepsy revealed by local EEG synchrony. Neuroimage. 2007 Mar; 35(1):140-8.
    View in: PubMed
    Score: 0.004
  98. Developmental outcome of epilepsy surgery in tuberous sclerosis complex. Epileptic Disord. 2005 Dec; 7(4):321-6.
    View in: PubMed
    Score: 0.003
  99. Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. J Neurosurg. 2005 Jun; 102(6):1133-6.
    View in: PubMed
    Score: 0.003
  100. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985 May 30; 312(22):1405-11.
    View in: PubMed
    Score: 0.003
  101. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol. 2004 Oct; 56(4):478-87.
    View in: PubMed
    Score: 0.003
  102. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology. 2003 Feb 25; 60(4):640-6.
    View in: PubMed
    Score: 0.003
  103. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27; 308(4):173-80.
    View in: PubMed
    Score: 0.003
  104. Endoscopic third ventriculostomy in patients with cerebrospinal fluid infection and/or hemorrhage. J Neurosurg. 2002 Sep; 97(3):519-24.
    View in: PubMed
    Score: 0.003
  105. Repeat endoscopic third ventriculostomy: is it worth trying? Childs Nerv Syst. 2001 Sep; 17(9):551-5.
    View in: PubMed
    Score: 0.003
  106. Long-term quality of life and neuropsychologic functioning for patients with CNS germ-cell tumors: from the First International CNS Germ-Cell Tumor Study. Neuro Oncol. 2001 07; 3(3):174-83.
    View in: PubMed
    Score: 0.002
  107. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May; 123(5):583-92.
    View in: PubMed
    Score: 0.002
  108. Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations: case report. Neurosurgery. 1996 Nov; 39(5):1031-4; discussion 1034-5.
    View in: PubMed
    Score: 0.002
  109. Complications of fourth-ventricular shunts. Pediatr Neurosurg. 1995; 22(6):309-13; discussion 314.
    View in: PubMed
    Score: 0.002
  110. A repressive coping style protecting from emotional distress in low-renin essential hypertensives. J Hypertens. 1994 May; 12(5):601-7.
    View in: PubMed
    Score: 0.002
  111. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol. 1991 Jan; 29(1):33-40.
    View in: PubMed
    Score: 0.001
  112. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987 Jan 08; 316(2):67-72.
    View in: PubMed
    Score: 0.001
  113. Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980 Jul 17; 303(3):125-9.
    View in: PubMed
    Score: 0.001
  114. Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. N Engl J Med. 1974 Oct 24; 291(17):861-5.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.